The Dietary Supplement Listing Act of 2026 is a federal bill that would, for the first time, require every dietary supplement sold in the United States to be listed product-by-product with the FDA. It is not law. It exists as two companion bills in the 119th Congress, both sitting in committee, and it is the third attempt at this idea after versions in 2022 and 2024 failed. If it passes, the work for supplement brands is mostly documentation: registering each SKU, keeping label and ingredient records current, and being able to produce supply-chain details on short notice. Here is exactly what it says, the timeline, the industry fight over it, and what it would mean for your catalog.
The key facts
| Item | Detail |
|---|---|
| What it is | A bill creating a mandatory FDA product-listing registry for dietary supplements |
| Bills | Senate: S.3677 (Sen. Dick Durbin, introduced Jan 15, 2026). House: H.R. 8370 (Rep. Maxine Dexter, M.D., introduced Apr 20, 2026) |
| Status | Introduced, referred to committee. Not passed. Prior versions (2022, 2024) failed |
| Mechanism | New Section 403D of the Federal Food, Drug, and Cosmetic Act |
| Who must comply | The “responsible person”: manufacturer, packer, or distributor named on the label (or the U.S. agent for foreign firms) |
| Scope | Product-by-product listing, not a one-time company registration |
| Does NOT do | Preserve DSHEA; no FDA premarket approval of supplements |
What would the Act actually require?
The heart of the bill is a registry. It amends the Federal Food, Drug, and Cosmetic Act with a new Section 403D, under which every dietary supplement marketed in the U.S. must be listed with the FDA. This is a per-product submission, not a single company registration, so a brand with 40 SKUs files 40 listings. The duty falls on the “responsible person,” meaning the manufacturer, packer, or distributor whose name appears on the label, or the designated U.S. agent for a foreign company.
For each product, the responsible person submits information that already lives on the label: the product name, a full list of ingredients (including the components of proprietary blends, reported to the FDA), an electronic copy of the label, allergen statements, directions for use, and the health and structure/function claims the product makes. The FDA then builds a publicly searchable database of this information, which consumers, competitors, journalists, and researchers could search by product name, ingredient, listing number, and other fields. Each product would receive a Dietary Supplement Listing Number.
The full bill text is on Congress.gov for both the Senate version, S.3677 and the House version, H.R. 8370.
What stays public versus confidential
Not everything submitted becomes public. The bill shields certain information from FOIA disclosure:
| Public in the database | Confidential / FOIA-shielded |
|---|---|
| Product names | Per-ingredient amounts inside proprietary blends |
| Ingredient lists | Contact information beyond what is on the label |
| Label copies | U.S. agent contact details for foreign entities |
| Serving and form information | Supplier and facility information (the on-demand items) |
| Health and structure/function claims |
The on-demand supply-chain provision
This is the part operations teams should note. The FDA could request, at any time, the address of every facility where a product is manufactured, packed, labeled, or stored, plus the name and address of every supplier of the dietary ingredients. That information is not published, but it must be produced within five calendar days of the request. A brand without organized, current supply-chain records would be exposed here. The legal analysis from Epstein Becker Green walks through this operational risk in detail.
What is the timeline?
Because the Act is not enacted, the clock has not started. The deadlines are written relative to the date of enactment:
- Supplements on the market on or before January 1, 2027 would need to be listed within 18 months of enactment.
- The FDA would have two years from enactment to stand up the public database.
- Beginning two years after enactment, the Dietary Supplement Listing Number would have to appear on each product’s label.
The bill also authorizes funding for the FDA to run it, roughly $7.9 million for fiscal year 2026 and about $6.6 million per year for 2027 through 2030.
What happens if you don’t comply?
This is where the bill has teeth. It amends Section 403 of the Federal Food, Drug, and Cosmetic Act so that a supplement is deemed misbranded if the responsible person fails to list it, fails to update a listing when the label changes, or fails to provide the on-demand information. Misbranding is a serious status; it can pull a product into enforcement and off the market. So the registry is not a voluntary nicety in this design. Non-compliance converts into a misbranding violation.
Why now?
The case for the bill is transparency and safety at scale. When the Dietary Supplement Health and Education Act (DSHEA) was passed in 1994, there were roughly 4,000 supplements on the market. Today estimates run from 80,000 to over 100,000, and the FDA still has no comprehensive, current inventory of what is actually being sold. Sponsors argue that gap undermines enforcement and consumer confidence. They also cite safety data: more than 2,000 adverse-event reports tied to supplements in 2023, with the FDA estimating the true annual figure exceeds 50,000 because of underreporting.
That 50,000 figure is contested. The Natural Products Association’s Dan Fabricant has argued the number has been challenged for decades, and opponents say it overstates the problem the bill is meant to solve. This is one of those areas where the underlying statistics are themselves part of the debate, so it is worth presenting as disputed rather than settled.
Where the industry actually stands
The supplement industry is split, and the politics shifted between the 2024 and 2026 versions, which is the most interesting part of the story.
On the support side, the Council for Responsible Nutrition (CRN) backs the 2026 bill, even though it opposed the 2024 version. CRN’s statement on the reintroduction frames it as a years-long push for a federal registry, and the group points to changes it considers meaningful, notably dropping a prior requirement that all marketing claims on a company’s website, not just claims on the label, be included in the registry. The Consumer Healthcare Products Association and the United Natural Products Alliance have taken cautiously constructive positions, supporting transparency while warning against burdens on compliant manufacturers.
On the opposition side, the Natural Products Association continues to oppose it, characterizing the bill as a “Trojan Horse” and a backdoor system that, in its view, bypasses the DSHEA framework Congress already established. Coverage of both positions is in NutraIngredients-USA’s reporting.
It is worth being precise about one defense the bill’s backers lean on: the Act preserves DSHEA and does not give the FDA authority to require premarket approval of supplements. Supporters use this to argue it is transparency, not a new gatekeeping regime; opponents argue a mandatory listing tied to misbranding penalties is gatekeeping by another name. Reasonable people in the industry land on both sides.
What it would mean for supplement sellers
If the Act passes, the practical reality for a supplement brand is administrative, not formulary. You would not have to change your products. You would have to account for them. Concretely, that means:
- Every SKU listed with the FDA, with the listing kept current whenever a label changes.
- Organized label and ingredient records, including proprietary-blend components reported to the FDA (though blend quantities stay confidential).
- Supply-chain documentation ready to produce in five days, covering manufacturing and storage facilities and ingredient suppliers.
- A listing number on each label once the database is live, which means a label revision cycle to plan for.
The brands that would struggle are the ones treating it as a last-minute paperwork exercise, then scrambling to list a large catalog under an 18-month clock while exposed to misbranding risk. The brands that would breeze through are the ones whose product records, labels, and supplier documentation are already clean.
There is a useful overlap for anyone selling on Amazon. Much of what this bill would require, accurate per-product data, label and ingredient records on file, and documented claims, is close to what Amazon’s supplement policy already enforces in practice. A brand that is genuinely compliant on Amazon today is most of the way to being ready for a federal listing regime, which reframes the work as consolidating records you should already have rather than building them from scratch.
What to watch
- Whether either bill moves out of committee. Both are currently referred and have not advanced. Two prior versions failed, so committee movement is the first real signal.
- Amendments. The 2026 version already softened from 2024. Further changes could shift industry positions again.
- The misbranding hook. Any change to the enforcement mechanism is the part with the most operational consequence for sellers.
The bottom line
The Dietary Supplement Listing Act of 2026 would create the first mandatory FDA product registry for supplements, requiring per-product listings, a public database, a listing number on labels, and on-demand supply-chain disclosure, with misbranding penalties for non-compliance. It preserves DSHEA and stops short of premarket approval. It is not law, it has failed twice before, and the industry is genuinely divided on it. For supplement sellers, the smart posture is to treat it as a strong signal of where oversight is heading and to get product, label, and supplier records in order now, because that preparation pays off under this bill, under Amazon’s existing policy, and under almost any version of what comes next.
FAQ
Is the Dietary Supplement Listing Act of 2026 law? No. It is proposed legislation in the 119th Congress, introduced as S.3677 in the Senate and H.R. 8370 in the House. Both are in committee and have not passed. Earlier versions in 2022 and 2024 failed.
What would the Act require supplement companies to do? List every product with the FDA, including product name, full ingredient list, label copy, allergen statements, directions for use, and claims. The FDA would build a public database and assign each product a listing number. Companies would also have to produce facility and supplier information on request within five days.
Does the Act require FDA approval before selling a supplement? No. It preserves the DSHEA framework and does not authorize FDA premarket approval. It is a listing and transparency requirement, not an approval gate.
What happens if a company doesn’t list its products? The Act would treat the product as misbranded, which can trigger enforcement and removal from the market. Failure to list, failure to update a listing, or failure to provide on-demand information all count.
When would companies have to comply? Deadlines run from the date of enactment, which has not happened. Products on the market on or before January 1, 2027 would need to be listed within 18 months of enactment, with the public database due within two years and listing numbers on labels two years after enactment.
Does the industry support it? It is split. The Council for Responsible Nutrition supports the 2026 version after opposing the 2024 one, and CHPA and UNPA are cautiously constructive, while the Natural Products Association opposes it as a backdoor around DSHEA.
What should supplement sellers do now? Get product, label, ingredient, and supplier records organized. That preparation is low-risk, helps with Amazon compliance today, and positions you to meet the deadlines quickly if the bill becomes law.
Free resource: Grab our supplement compliance checklist for Amazon and FDA readiness to get your product, label, and supplier records in order before any deadline starts. [Link]
Written by the team at Fussy Penguins, the Amazon team built exclusively for supplement brands. We work with supplement founders on PPC, listing optimization, compliance, and growth. [Learn more about our work →]
Keep reading: What the 2026 FDA, FTC, and MAHA supplement proposals mean for Amazon sellers · Which cGMP certifications Amazon accepts · How to reinstate a deactivated supplement listing
Read more from Fussy Penguins.
Explainers, playbooks, opinions, and short notes — written by operators, for operators.